[Skip to Navigation]
Sign In
Comment & Response
August 20, 2020

Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer—Not All That Glitters Is Gold

Author Affiliations
  • 1Vita-Salute San Raffaele University, Milan, Italy
  • 2Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
JAMA Oncol. 2020;6(10):1638-1639. doi:10.1001/jamaoncol.2020.2829

To the Editor Phillips et al1 have reported a phase 2 randomized clinical trial assessing the role of stereotactic body radiotherapy in men with up to 3 nodal and/or bone metastases after primary treatment for prostate cancer. The authors should be commended for this trial, which showed higher efficacy of metastasis-directed therapy (MDT) without concomitant systemic treatment compared with observation with regard to 6-month progression-free survival. However, unfortunately, this trial fails to shed light on the correct management of oligorecurrent prostate cancer for the following reasons.

Add or change institution